Kazia Therapeutics Crescita futura

Criteri Future verificati 2/6

Si prevede che Kazia Therapeutics aumenterà gli utili e i ricavi rispettivamente del 54.8% e 69.8% all'anno, mentre si prevede che l'EPS crescerà del 64.4% all'anno.

Informazioni chiave

54.8%

Tasso di crescita degli utili

64.40%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	25.1%
Tasso di crescita dei ricavi	69.8%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	01 Jul 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Seeking Alpha • Jul 06

Kazia gains on FDA’s rare pediatric disease designation for childhood cancer therapy

The ADRs of Australian biotech Kazia Therapeutics (NASDAQ:KZIA) gained 8% Wednesday after the company announced that the U.S. Food and Drug Administration (FDA) granted the Rare Pediatric Disease Designation for an experimental therapy targeted at a form of childhood cancer. Paxalisib a brain-penetrant inhibitor received the designation as a treatment for atypical rhabdoid / teratoid tumors (AT/RT), a rare and highly aggressive childhood brain cancer, Kazia (KZIA) said in a press release. In awarding the RPD tag, the federal agency picks drug candidates targeted at serious and life-threatening diseases affecting less than 200K individuals in the U.S. with a primary impact on children aged 18 years or younger. If a drug with a rare pediatric disease designation wins FDA approval, the sponsor of its marketing application is entitled to receive a Priority Review Voucher (PRV) from the regulator. The PRVs valued at more than $100M historically, can be redeemed to receive a priority review for any subsequent marketing application, or it can be sold. In June, Kazia (KZIA) announced that the FDA awarded orphan drug designation for Paxalisib for the same condition.

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:KZIA - Stime future degli analisti e dati finanziari passati (AUD Millions )
Data	Ricavi	Utili	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2029	18	-27	N/A	-26	2
6/30/2028	0	-35	N/A	-26	2
6/30/2027	0	-30	N/A	-29	2
6/30/2026	0	-26	N/A	-28	2
12/31/2025	2	-23	-14	-14	N/A
9/30/2025	2	-22	-14	-14	N/A
6/30/2025	2	-21	-13	-13	N/A
3/31/2025	2	-25	-12	-12	N/A
12/31/2024	3	-28	-12	-12	N/A
9/30/2024	2	-28	-11	-11	N/A
6/30/2024	2	-27	-10	-10	N/A
3/31/2024	1	-21	-11	-11	N/A
12/31/2023	0	-16	-13	-13	N/A
9/30/2023	0	-18	-14	-14	N/A
6/30/2023	0	-20	-15	-15	N/A
3/31/2023	0	-23	-18	-18	N/A
12/31/2022	N/A	-25	-20	-20	N/A
9/30/2022	0	-25	-21	-21	N/A
6/30/2022	0	-25	-23	-23	N/A
3/31/2022	8	-20	-15	-15	N/A
12/31/2021	15	-15	-8	-8	N/A
9/30/2021	15	-12	-9	-9	N/A
6/30/2021	15	-8	-9	-9	N/A
3/31/2021	8	-11	-14	-14	N/A
12/31/2020	0	-13	-18	-18	N/A
9/30/2020	1	-13	-14	-14	N/A
6/30/2020	1	-12	-9	-9	N/A
3/31/2020	1	-11	-7	-7	N/A
12/31/2019	1	-10	-5	-5	N/A
9/30/2019	1	-10	N/A	-6	N/A
6/30/2019	1	-10	N/A	-7	N/A
3/31/2019	2	-11	N/A	-6	N/A
12/31/2018	2	-12	N/A	-5	N/A
9/30/2018	3	-9	N/A	-7	N/A
6/30/2018	3	-6	N/A	-9	N/A
3/31/2018	4	-6	N/A	-10	N/A
12/31/2017	6	-6	N/A	-12	N/A
9/30/2017	7	-8	N/A	-12	N/A
6/30/2017	9	-11	N/A	-11	N/A
3/31/2017	7	-12	N/A	-12	N/A
12/31/2016	5	-12	N/A	-12	N/A
9/30/2016	4	-12	N/A	-12	N/A
6/30/2016	3	-12	N/A	-12	N/A
3/31/2016	3	-10	N/A	-12	N/A
12/31/2015	3	-9	N/A	-12	N/A
9/30/2015	2	-8	N/A	-9	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che KZIA rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che KZIA rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che KZIA rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di KZIA ( 69.8% all'anno) crescerà più rapidamente del mercato US ( 12.7% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di KZIA ( 69.8% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di KZIA è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/07/05 06:54
Prezzo dell'azione a fine giornata	2026/07/02 00:00
Utili	2025/12/31
Utili annuali	2025/06/30

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Kazia Therapeutics Limited è coperta da 6 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Kambiz Yazdi	BTIG
Soo Romanoff	Edison Investment Research
Sean Lee	H.C. Wainwright & Co.

Kazia Therapeutics Crescita futura

Criteri Future verificati 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates upgraded to AU$0.016 loss

Recent updates

New major risk - Revenue and earnings growth

Kazia Therapeutics Limited Announces Appointment of James Levine to Chief Financial Officer, Effective June 1, 2026

Consensus EPS estimates upgraded to AU$0.016 loss

Kazia Therapeutics Expands Ongoing Phase 1B Trial of Paxalisib in Advanced Breast Cancer

Kazia Therapeutics Limited Appoints Dr. Sudha Rao as Chief Scientific Officer

Kazia Therapeutics Limited Expands Oncology Platform with First-In-Class SETDB1 Inhibitor Drug Development Platform

First half 2026 earnings released: AU$4.02 loss per share (vs AU$12.29 loss in 1H 2025)

New major risk - Negative shareholders equity

Kazia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $100 million.

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1B Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations Including TNBC and HER2+

Kazia Therapeutics Limited announced that it expects to receive $50.000896 million in funding from ADAR1 Capital Management, LLC, Ikarian Capital, LLC, Stonepine Capital Management LLC, Velan Capital Partners LP, Revach Capital Management LLC

Kazia Therapeutics Limited Achieves Initial iCR (Immune- Complete Response) in Metastatic TNBC and Delivers Fourth Quarter Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy

Kazia Therapeutics Limited announced delayed 20-F filing

Kazia Therapeutics Limited Plans to Request Type C Meeting with U.S. Food & Drug Administration to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA Initiative Project FrontRunner

Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic Tnbc Patient Treatment with Paxalisib-Immunotherapy Regimen

Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage Iv Her2-Positive Breast Cancer with Paxalisib Monotherapy

Kazia Therapeutics Limited announced that it expects to receive $2.049992 million in funding

Kazia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $1.906196 million.

Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen Achieves >50% Reduction in Circulating Tumor Cells in Phase 1B Trial

First half 2025 earnings released: AU$12.29 loss per share (vs AU$18.40 loss in 1H 2024)

Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer

Kazia Therapeutics Limited Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer

New minor risk - Financial data availability

High number of new and inexperienced directors

Kazia Therapeutics Limited Announces the Launch of A Groundbreaking Trial with Paxalisib in Combination with Immunotherapy in Women with Advanced Breast Cancer

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of $1.999922 million.

Kazia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $2 million.

Kazia Therapeutics Limited Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA

Kazia Therapeutics Limited Announces to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium

Kazia Therapeutics Limited Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

Kazia Therapeutics Limited announced delayed 20-F filing

New minor risk - Financial data availability

Kazia Therapeutics Announces Presentation of Evt801 Clinical Data At 15 Biennial Ovarian Cancer Research Symposium

New major risk - Market cap size

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of $10 million.

Kazia Therapeutics Limited Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

Kazia Therapeutics Limited Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients

Kazia Therapeutics Limited announced that it expects to receive $15 million in funding from Alumni Capital LP

New major risk - Share price stability

New major risk - Financial position

New minor risk - Financial data availability

Kazia Therapeutics Limited Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

Kazia Therapeutics Limited Announces Appointment of Board Members

Kazia Therapeutics Limited Announces Executive Changes

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of $1.981756 million.

Kazia Therapeutics Announces Receipt of Nasdaq Minimum Bid Notification

High number of new and inexperienced directors

Kazia Therapeutics Provides Preliminary Update from Ongoing Phase 2 Study of Paxalisib in Primary Cns Lymphoma

Kazia Therapeutics Limited Announces Clinical Data At ESMO 2023 from Ongoing Phase 1 ESMO Study

Kazia Therapeutics Limited Announces Acceptance of Late-Breaking Abstracts and Oral Presentation of Pnoc022 Clinical Data At 2023 Society for Neuro-Oncology Annual Meeting

Kazia Therapeutics Limited, Annual General Meeting, Nov 08, 2023

Kazia Therapeutics Limited Announces Change to Board of Directors

Kazia Therapeutics Limited Appoints John Friend as Managing Director

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.5 million.

Kazia Therapeutics Limited Receives Fast Track Designation from FDA for Treatment of Solid Tumor Brain Metastases Harboring PI3K Pathway Mutations in Combination with Radiation Therapy

Kazia Therapeutics Limited Announces Phase II Clinical Study to Investigate Paxalisib in Recurrent/Progressive IDH-Mutant Grade 2 & 3 Glioma

Kazia Therapeutics Limited Appoints Ms. Ebru Davidson to its Board

Kazia gains on FDA’s rare pediatric disease designation for childhood cancer therapy

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Fonti dei dati

Modello di analisi e Snowflake

Metriche di settore e industriali

Fonti analitiche